ANKYLOSING SPONDYLITIS

Ankylosing Spondylitis (AS), a form of spondylarthritis (SpA), is a systemic inflammatory rheumatic disease. Although the exact pathogenesis of AS is not yet fully understood, as with rheumatoid arthritis, the swelling, pain, and joint damage that characterize AS are considered to be the result of complex autoimmune and inflammatory processes based on both environmental and genetic factors.

IAG’s team has extensive expertise and track record in supporting the development of novel therapeutics in AS and SpA and helping to take these drugs from early phase all the way to phase 3 and approval. Our expertise is in use of

• X-ray
• MRI
• Dynamic Contrast Enhanced MRI
• CT

to support disease diagnosis and assessment of treatment response.

IAG’s team plays an active role in the scientific community and have led the development of novel scoring systems for early assessment of synovial inflammatory changes, quantification of inflammation and quantitative assessment of erosive changes. Our extensive experience in using radiography, which is a conventional gold standard method for assessment of structural damage in spine and sacroiliac joints. Our medical science team have worked with drug developers in trials incorporating Computed Tomography (CT), which is a more sensitive method for assessment of structural changes in the spine and sacroiliac joints.

In many trials, early diagnosis of sacroiliitis, the most frequent clinical symptom often accompanied by inflammatory back pain, and other inflammatory lesions of the spine such as spondylitis and spondylodiscitis, can be visualized early by magnetic resonance imaging (MRI), especially using fat saturating STIR or Gd-Enhanced Dynamic MRI sequences. IAG’s team helped to integrate ultrasonography and MRI into the trials for visualization and quantification of peripheral arthritis and enthesitis.

About IAG, Image Analysis Group

IAG is a unique partner to life sciences companies developing new treatment and driving the hope of the up-coming precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™, our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes.

Acting as imaging Contract Research Organization, IAG’s experts also recognize the significance of a comprehensive approach to asset development. They actively engage in co-development projects with both private and public sectors, demonstrating a commitment to cultivating collaboration and advancing healthcare solutions.

Contact our expert team: imaging.experts@ia-grp.com